Technetium Tc99m etarfolatide

Drug Profile

Technetium Tc99m etarfolatide

Alternative Names: 99mTC-Etarfolatide; EC 145 companion diagnostic - Endocyte; EC-20; Etarfolatide; Etarfolatide TC99m; Folate-Tc99m; FolateScan; FOLCEPRI; In 111-EC20; NMK 20; Tc 99m-EC20; Vintafolide companion diagnostic

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte
  • Developer Endocyte; Nihon Medi-Physics
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pituitary cancer; Renal cell carcinoma
  • Preregistration Submission Withdrawal Ovarian cancer
  • No development reported Solid tumours
  • Discontinued Inflammation

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(In volunteers) in Japan (IV, Injection)
  • 28 Aug 2015 Development of technetium etarfolatide is still ongoing for Pituitary cancer and Renal cell carcinoma (Diagnosis) in USA (Endocyte pipeline, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top